Fetuin A Chelate Chromatography for High-Purity Plasma Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective preparation methods for Fetuin A from biological liquids, particularly from human plasma, as current methods are inefficient and can lead to degradation or denaturation, and existing treatments for osteoporosis are not sufficient in preventing non-vertebral fractures and have significant side effects.
Innovation Solution
A method involving chelate chromatography is used to purify the chromatography step of adsorption of Fetuin A on a chelate chromatography material, specifically using immobilized metal affinity chromatography (IMAC) resin, which allows for efficient purification of Fetuin A from biological fluids by forming complexes with metal ions like Zn2+, Cu2+, Cd2+, Hg2+, and Fe2+, and Cd2+, and Fe2+, and Fe2+, and eluting the Fetuin A can then be purified in a very efficient way from a Cohn fraction, especially from adult plasma. The chromatography step of the inventive method may be performed as column chromatography or batch chromatography. Especially for industrial purposes column chromatography may be preferred.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional preparation methods are used to prepare Fetuin A from biological liquids, then the process can be simplified, but the purity and stability of Fetuin A deteriorate due to degradation or denaturation
Solution Approach 1:
The preparation process is divided into distinct functional stages: (1) protein precipitation using polyethylene glycol to concentrate Fetuin A, (2) chelate chromatography using immobilized metal ions to selectively bind and purify Fetuin A, and (3) elution to release purified protein. This segmentation allows each step to be optimized independently, maintaining purity while simplifying the overall process.
Solution Approach 2:
The patent introduces chelating agents (immobilized metal ions such as Ca2+, Mn2+, Zn2+) as intermediary substances that mediate the interaction between Fetuin A and the chromatography medium. These intermediaries enable selective binding based on metal ion coordination, achieving high purity separation without direct harsh interactions that would cause denaturation.
2Reliability
If existing osteoporosis treatments are used, then vertebral fracture prevention is improved, but non-vertebral fracture prevention and safety profile deteriorate
Solution Approach 1:
The patent changes the therapeutic parameter from conventional osteoporosis drugs (bisphosphonates, estrogens) to Fetuin A protein replacement therapy. This parameter change shifts the mechanism of action from suppressing bone resorption to providing a protein that inhibits calcification and promotes bone formation, thereby improving safety profile while maintaining efficacy in preventing both vertebral and non-vertebral fractures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity and yield of Fetuin A, with purities over 60% (w/w) and up to 80% (w/w), and can be integrated into existing plasma fractionation processes, minimizing degradation or denaturation, and the pharmaceutical composition is effective in treating Fetuin A deficiencies and related bone disorders.
Implementation Method 1
The chromatography step comprises adsorption of Fetuin A on a chelate chromatography material, wherein the material is charged with a doubly charged cation
Implementation Method 2
The chromatography step comprises adsorption of Fetuin A on a chelate chromatography material
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a method for preparing Fetuin A from a biological liquid. The method comprises a chromatography step of adsorption of Fetuin A on a chelate chromatography material, wherein the resin is charged with a doubly charged cation, and eluting the Fetuin A. Moreover, the invention provides a pharmaceutical composition comprising Fetuin A.